BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?

Boston Scientific (market cap $142.4B) and ResMed ($35.72B) are positioned for above-market growth driven by product momentum, acquisitions and operational initiatives; Boston Scientific highlights WATCHMAN FLX/FLX Pro adoption, a projected ~20% WATCHMAN market expansion, FARAPULSE PFA labeling expansion, and multiple 2025 tuck‑in acquisitions while emerging markets represented 15% of sales in the first nine months of 2025. Analyst consensus expects Boston Scientific 2025 EPS of $3.04 (+21.1% YoY, consensus up $0.01 in 60 days) and ResMed fiscal 2026 EPS of $10.84 (+13.5% YoY, consensus up 3.3% in 60 days); 12‑month share moves are modest (BSX +6.8%, RMD +5.8%) and both trade below median forward P/S. The combination of new device launches, AI-enabled features (ResMed’s Dawn and Smart Comfort), margin improvement programs and targeted M&A underpin a favorable view for BSX in particular, with Zacks ranks of #2 (Buy) for BSX and #3 (Hold) for RMD.

Analysis

Market structure: Boston Scientific (MCAP ~$142B) is the clear direct beneficiary of accelerated EP/LAAC adoption (WATCHMAN market mgmt forecasts ~20% expansion) and tuck-in M&A; winners also include suppliers of PFA and MedSurg consumables. Losers would be portions of the oral-anticoagulant revenue pool and competing device incumbents if WATCHMAN/FLX adoption accelerates; pricing power for BSX rises where procedural substitutes exist. Supply/demand: underlying device demand tied to ~7% CAGR and recurring consumable demand (ResMed masks/CPAP supplies) supports predictable revenue; short-term supply risk centers on component/sterilization capacity and EM FX in markets where EM sales are only ~15% today.

Risk assessment: Tail risks include adverse CHAMPION readout (H1 2026), FDA safety flags on PFA, reimbursement shifts away from devices, or EM currency shocks; each could knock 15–30% off forward multiples. Time horizons: immediate (days-weeks) tradeable around upcoming earnings and FDA milestones; short-term (3–12 months) driven by CHAMPION, Dawn/AI uptake metrics and integration of acquisitions; long-term (2–5 years) depends on EM penetration and product launches (WATCHMAN Elite late 2027/2028). Hidden deps: BSX adoption hinges on clinician training and hospital capital cycles; RMD growth hinges on China/India DTC traction and AI reimbursement.

Trade implications: Tactical overweight BSX vs peers — asymmetric upside into CHAMPION and expanded PFA label; consider modest underweight or neutral position in RMD until DTC metrics prove sustainable. Use options to express event risk: buy-dated call spreads on BSX into H1 2026 and buy protective puts underwritten by sell-call spreads on RMD if holding. Cross-asset: stronger BSX/RMD prints tighten credit spreads for MedTech, modestly strengthen USD via tech/health outperformance; commodities impact minimal.

Contrarian angles: Consensus understates integration risk from multiple BSX tuck-ins — expect 1–3 quarters of margin pressure before scale benefits, a potential 5–8% EPS drag short-term. Conversely, RMD’s AI-enabled comfort personalization and recurring consumables could be underappreciated, offering upside if adoption >10% penetration in key markets within 12 months. Watch for unintended pushback: rapid WATCHMAN uptake could trigger payer scrutiny or competitive pricing moves, creating a binary outcome around CHAMPION data.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in BSX (ticker: BSX) within 30 days to play WATCHMAN and PFA upside; set tactical stop-loss at -12% and take-profit at +25% over 12 months, trim 50% if Zacks/consensus EPS revision for BSX falls >5% in a quarter.
• Implement a relative-value pair: long BSX (1.5% weight) / short RMD (0.75% weight) over a 6–12 month horizon to exploit catalyst divergence (CHAMPION H1 2026 vs slower DTC monetization); unwind if RMD consensus EPS increases >5% or BSX misses revenue by >3%.
• Buy a 9–12 month call spread on BSX sized to 1% portfolio risk (debit spread) ahead of H1 2026 CHAMPION data to cap cost and capture upside; strike widths sized to target 20–40% upside. Simultaneously, if holding RMD, sell a 3-month out-of-the-money covered call to collect premium if implied vol >18%, or buy a 3-month protective put if worried about near-term DTC disappointments.
• Reallocate +3% from large-cap pharma into MedTech/Health Equipment (increase BSX exposure) over the next 3 months, funded by trimming non-cyclical pharma names that lack device exposure; revisit allocation after CHAMPION readout and RMD quarterly DTC revenue growth surpasses 5% month-over-month for three consecutive months.